AFFYMAX INC (AFFY) [Rocket]

Date Filed	Type	Description
05/31/2011	BW	Affymax and Takeda Announce the Submission of a New Drug Application for Peginesatide for the Treatment of Anemia Associated with Chronic Renal Failure in Patients on Dialysis
04/28/2011	BW	Affymax and Takeda Report Additional Phase 3 Clinical Trial Data for Peginesatide in Dialysis Patients at the National Kidney Foundation Spring Clinical Meetings
04/27/2011	BW	Affymax Announces Upcoming Webcasts and Conference Participation
04/12/2011	BW	Affymax Names Andrew Blair, M.D., as Vice President of Medical Affairs
03/23/2011	BW	Affymax and Takeda to Present Additional Peginesatide Phase 3 Data in Dialysis Patients at the National Kidney Foundation (NKF) 2011 Spring Clinical Meeting
03/18/2011	BW	Affymax Announces Pricing of Public Offering of Common Stock
03/17/2011	BW	Affymax Announces Proposed Public Offering of Common Stock
03/10/2011	BW	Affymax® Reports Year End 2010 Financial Results
03/01/2011	BW	Affymax to Present at Cowen and Company's 31st Annual Health Care Conference
02/25/2011	BW	Affymax to Present at RBC Capital Markets' Healthcare Conference
12/07/2010	BW	Affymax to Present at the Deutsche Bank 2010 BioFEST Conference
11/29/2010	BW	Affymax and Takeda Confirm U.S. Registration Strategy for Investigational Drug, Hematide™/Peginesatide, Following Meeting with FDA
11/24/2010	BW	Affymax to Present at Piper Jaffray 22nd Annual Health Care Conference
11/16/2010	BW	Affymax Names Herb Cross as Chief Accounting Officer and Vice President of Finance
11/09/2010	BW	Affymax to Present at Lazard Capital Markets Healthcare Conference
11/05/2010	BW	Affymax® Reports Third Quarter 2010 Financial Results
10/06/2010	BW	Affymax® Announces Decision in Arbitration Against JNJ
08/31/2010	BW	Affymax® Announces Upcoming Webcasts and Conference Participation
08/04/2010	BW	Affymax® Reports Second Quarter 2010 Financial Results
06/22/2010	BW	Affymax® Receives $30 Million Milestone Payments for Database Lock of Phase 3 Clinical Trials for Hematide™/peginesatide
06/21/2010	BW	Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for Investigational Drug, Hematide™/peginesatide, to Treat Anemia in Chronic Renal Failure With Some Differences Noted in Secondary Analyses
06/20/2010	BW	Affymax® to Hold Conference Call and Webcast on Monday, June 21, 2010 at 8:00 a.m. Eastern Time
04/12/2010	BW	Affymax Names John A. Orwin President and Chief Operating Officer
03/31/2010	BW	Affymax Promotes Sylvia Wheeler to Vice President of Corporate Communications
03/30/2010	BW	Affymax and Takeda to Present HematideTM/peginesatide Phase 2 Data at the National Kidney Foundation 2010 Spring Meeting
03/16/2010	BW	Affymax to Present at the Barclays 2010 Global Healthcare Conference
03/04/2010	BW	Affymax® Reports Year End 2009 Financial Results